Able to Read and Understand Informed Consent
Item
The subject must be able to read and understand the informed consent fonn and provide written infonned consent, indicating the subject's understanding of the purpose of the study and willingness to comply with all study procedures described in the protocol, including all sleeplaboratory restrictions and procedures.
boolean
C0586740 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0162340 (UMLS CUI [1,3])
C0525058 (UMLS CUI [2])
Gender and Age
Item
Male and female subjects 18 through 64 years of age (inclusive).
boolean
C0079399 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
Diagnosis of Primary Insomnia
Item
Diagnosis of Primary Insomnia, based on Diagnostic and Statistical Manual of Mental Disorders.
boolean
C0332137 (UMLS CUI [1,1])
C0393760 (UMLS CUI [1,2])
Self Reported Sleep History
Item
The subject's self-reported sleep history includes at least three months of a usual (i.e. > 3 nights per week) TST of less than 6.0 hours, a sleep onset latency (SOL) of at least 30 minutes and WASO >= 60 minutes.
boolean
C2700446 (UMLS CUI [1,1])
C0037317 (UMLS CUI [1,2])
Time in Bed
Item
Time in bed between 6.5 and 8.5 hours for least 5 nights per week over the preceding 3 months.
boolean
C4289366 (UMLS CUI [1])
Bed Time
Item
Bed time between 21.00 and 24.00 hours that does not vary by more than +/- 2 hours over the preceding 3 months. Bedtime (lights out) will be confirmed by a one-week diary completed before the first PSG screening session (Visits 2/3).
boolean
C0521112 (UMLS CUI [1])
Sleep Variables from Polysomnography
Item
The sleep variables obtained from the two screening PSG sessions (with single-blinded placebo administration at each night) must fall within the following ranges: - TST between 240 and 420 minutes inclusive on both nights - Mean LPS of 20 minutes or more, and LPS not < 15 minutes on either night - Mean WASO of 60 minutes or more, and WASO not< 45 minutes on either night
boolean
C0162701 (UMLS CUI [1,1])
C0037317 (UMLS CUI [1,2])
Child Bearing Potential, Use of Contraception
Item
A female subject is ehgible to participate if she is of: - Non-childbearing potential - Child-bearing potential and agrees to use one of the contraception methods listed in Section 4.5 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. - Female subjects must agree to use contraception until 3 days post-last dose.
boolean
C1960468 (UMLS CUI [1])
C1524063 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Health Status
Item
The subject is in good health as determined by medical and psychiatric history, physical examination, ECG, and serum chemistry, hematology, serology, and urinalysis results.
boolean
C0018759 (UMLS CUI [1])
C0262926 (UMLS CUI [2])
C0748059 (UMLS CUI [3])
C0031809 (UMLS CUI [4])
C1623258 (UMLS CUI [5])
C1883010 (UMLS CUI [6])
C0474523 (UMLS CUI [7])
C0036743 (UMLS CUI [8])
C0042014 (UMLS CUI [9])
Symptoms of Sleep Disorder
Item
Symptoms/signs that are consistent with any primary sleep disorder other than primary insomnia, e.g. sleep apnea, restless leg syndrome, circadian rhythm disorder.
boolean
C0851578 (UMLS CUI [1])
C0033139 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C0037315 (UMLS CUI [3])
C0035258 (UMLS CUI [4])
C0813142 (UMLS CUI [5])
Clinically Significant Psychiatric Disorder Axis I
Item
Any clinically significant Axis I psychiatric disorder other than primary insomnia as defined by DSM-IV-TR.
boolean
C0270287 (UMLS CUI [1,1])
C0004936 (UMLS CUI [1,2])
C0750502 (UMLS CUI [1,3])
History of Mental Disorders
Item
Subject has a recent history (12 months) of mood or other mental disorders that the investigator regards as accounting for the insomnia.
boolean
C0004936 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0566251 (UMLS CUI [2,1])
C0917801 (UMLS CUI [2,2])
Beck Depression Inventory Score
Item
Subject has a Beck Depression Inventory (Version II) [Beck, 1996] total score of29 or greater at the Screening Visit (Visit l) or at Visit 4 (if2 weeks have elapsed between screening visit and randomization).
boolean
C2960571 (UMLS CUI [1])
History of Substance Abuse, Alcohol, Narcotic, Benzodiazepine
Item
History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence (with the exception of tobacco use) within the past 12 months as defined by DSMIV-TR.
boolean
C1299544 (UMLS CUI [1])
C0085762 (UMLS CUI [2])
C0524661 (UMLS CUI [3])
C0005064 (UMLS CUI [4])
C0038580 (UMLS CUI [5])
Positive Urine Drug Screens
Item
Positive urine drug screen ( i.e. amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, or opiates) at Screening Visit (Visit I ). A repeat test will not be allowed if the result is positive.
boolean
C0743300 (UMLS CUI [1])
C0002667 (UMLS CUI [2])
C0004745 (UMLS CUI [3])
C0005064 (UMLS CUI [4])
C0006864 (UMLS CUI [5])
C0009170 (UMLS CUI [6])
Positive Alcohol Breath Test
Item
Positive alcohol breath test at Screening Visit (Visit l), i.e. alcohol level greater than 0.015% after subject being told that they must not drink for 8 hours preceding the Screening Visit (Visit I). A repeat test will not be allowed if the result is positive.
boolean
C0202306 (UMLS CUI [1])
History of Neurological Abnormality or History of Seizure
Item
Any history of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (except febrile seizure).
boolean
C0262926 (UMLS CUI [1,1])
C0036572 (UMLS CUI [1,2])
C0027765 (UMLS CUI [2,1])
C0262926 (UMLS CUI [2,2])
Unstable Medical Disorder
Item
Subjects with an unstable medical disorder or a disorder that would likely interfere with the action, absorption, distribution, metabolism or excretion of vestipitant, may pose a safety concern, or interfere with accurate assessment of efficacy or safety.
boolean
C3843040 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0521102 (UMLS CUI [2,1])
C0000854 (UMLS CUI [2,2])
C0521102 (UMLS CUI [3,1])
C1378698 (UMLS CUI [3,2])
C0521102 (UMLS CUI [4,1])
C0025519 (UMLS CUI [4,2])
C0521102 (UMLS CUI [5,1])
C0036043 (UMLS CUI [5,2])
C0521102 (UMLS CUI [6,1])
C0220825 (UMLS CUI [6,2])
ECG Abnormalities
Item
Subjects have any screening electrocardiography (ECG) parameter outside of the Sponsor-specified ranges as determined by a central ECG reader (See Appendix 2: ECG Parameters); the ECG may be repeated once to see if the parameter returns to within range but any such abnonnality must be resolved by the first screening PSG session (Visit 2).
boolean
C0522055 (UMLS CUI [1])
ECG Abnormalities
Item
Subjects have any ECG finding that in the Investigator's judgement is considered to be clinically significant and not resolved by the first day of screening PSG session (Visit 2) (even if not outside of Sponsorspecified ranges in Appendix 2: ECG Parameters).
boolean
C0522055 (UMLS CUI [1])
HIV, Hepatitis B or Hepatitis C
Item
Known seropositivity for human immunodeficiency virus (HfV), Hepatitis B, or Hepatitis C.
boolean
C0019682 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Positive Serum HCG Test
Item
Women having a positive serum HCG pregnancy test at the Screening Visit (Visit l), a positive urine pregnancy dipstick during the screening PSG sessEon (Visit 2) or at Visit 4 (Randomization), or who are lactating or planning to become pregnant within 14 weeks following the Screening Visit (Visit I).
boolean
C0430060 (UMLS CUI [1])
Laboratory Tests Abnormal
Item
Subjects have any screening laboratory value outside of the Sponsorspecified ranges at the Screening Visit (Visit 1) (See Appendix 3: Laboratory Parameters). Testing may be repeated once to see if value returns to within range but any such laboratory abnormality must be resolved by the screening PSG session (Visit 2).
boolean
C0438215 (UMLS CUI [1])
Laboratory Results Abnormality
Item
Subjects have any laboratory abnormality that in the Investigator's judgement is considered to be clinically significant and not resolved by the first day of the screening PSG session (Visit 2) (even if not outside of Sponsor-specified ranges in Appendix 3: Laboratory Parameters).
boolean
C1254595 (UMLS CUI [1,1])
C1704258 (UMLS CUI [1,2])
Euthyroid
Item
Subjects who are not euthyroid based on laboratory tests at the screening visit. Subjects maintained on thyroid medication must be euthyroid for a period of at least 6 months prior to the Screening Visit (Visit I), with no dose changes.
boolean
C0117002 (UMLS CUI [1])
BMI
Item
Body mass index of 34 or more at the Screening Visit (Visit I).
boolean
C1305855 (UMLS CUI [1])
Apnea-hypopnea Index
Item
Apnea-hypopnea index of IO or more on Night I screening PSG (Visit 2). Subjects failing Night I screening PSG should not be screened on Night 2 (Visit 3).
boolean
C2111846 (UMLS CUI [1])
Periodic Limb Movements with Arousal
Item
Periodic limb movements with arousal of 10 or more/hour of sleep on Night I screening PSG (Visit 2). Subj ects failing Night I screening PSG should not be screened on Night 2 (Visit 3).
boolean
C0596840 (UMLS CUI [1])
C0003808 (UMLS CUI [2])
Recent Nightshift or Rotating Shift
Item
Nightshift or rotating shift-work within I month preceding the Screening Visit (Visit I) or during the study period.
boolean
C1658633 (UMLS CUI [1])
C0555008 (UMLS CUI [2])
Planned Long Distance Travel
Item
Planned travel across more than 3 time zones during the study or in the 2 weeks preceding the Screening Visit (Visit I).
boolean
C0040802 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
Regular Napping
Item
Regular napping, i.e. more than 2 naps per week.
boolean
C0870935 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
Caffeine or Xanthine Consumption
Item
Consumption of beverages or foods containing a total of 300 mg or more per day on average of caffeine or other xanthines ( e.g. coffee, cola, tea, chocolate) over the one month preceding the Screening Visit (Visit I)
boolean
C0948365 (UMLS CUI [1])
C0043314 (UMLS CUI [2])
Smoking Status
Item
Smoking more than 1 pack of cigarettes (20) per day on average over the one month preceding the Screening Visit (Visit 1), or routinely a smoker during the night.
boolean
C1519386 (UMLS CUI [1])
Alcohol Consumption
Item
Typical consumption of more than 14 alcoholic units in any week, or more than 3 alcoholic units in any single day, over the one month preceding the Screening Visit (Visit L)
boolean
C0001948 (UMLS CUI [1])
Use of Psychotropic Medications
Item
Use of any psychotropic medications, such as benzodiazepines and other anxiolytics, barbiturates, and narcotics, or other medications, including over-the-counter (OTC) products, that may affect sleep/wake function within I week or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit I) or need to use any of these medications at any time during the study.
boolean
C0033978 (UMLS CUI [1])
C0005064 (UMLS CUI [2])
C0040616 (UMLS CUI [3])
C0004745 (UMLS CUI [4])
C0027415 (UMLS CUI [5])
C0013227 (UMLS CUI [6,1])
C0205394 (UMLS CUI [6,2])
C2709201 (UMLS CUI [7,1])
C0013227 (UMLS CUI [7,2])
Recent Cognitive Behavioral Therapy
Item
Cognitive Behavioral Therapy started within 1 month prior to the screening vis it ( i.e. within one month of Visit I).
boolean
C0009244 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Chronic or Systemic Corticosteroids
Item
Has received chronic therapy with systemic corticosteroids within 12 months prior to the Screening Vis it (Vis it I). Asthmatic subjects using an inhaled corticosteroid as part of their regular maintenance therapy are eligible provided their asthma is under control (especially as night).
boolean
C0001617 (UMLS CUI [1,1])
C0220922 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0332300 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0004096 (UMLS CUI [2,3])
History of Depot Neuroleptic Use
Item
Any history of depot neuroleptic use.
boolean
C2585377 (UMLS CUI [1])
Drugs Metabolized by CYP3A4
Item
All other drugs metabolized via the P450 3A4 pathway and CYP3A4 inducers/inhibitors, including over-the-counter (OTC) and herbal products, must be discontinued from screening and are not allowed for the duration of the study (See Appendix 4).
boolean
C0013227 (UMLS CUI [1,1])
C1142644 (UMLS CUI [1,2])
C1524026 (UMLS CUI [1,3])
C3830624 (UMLS CUI [2,1])
C3830625 (UMLS CUI [2,2])
C2709201 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
History of Allergic Reaction or Adverse Effects to Vestipant
Item
Subjects who have a history of allergic reaction to, or significant adverse effects from vestipitant or closely related compounds.
boolean
C1527304 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0559546 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
Hypersensitivity to NK1 Antagonists
Item
Subjects who have had hypersensitivity or intolerance to NK1 antagonists.
boolean
C0020517 (UMLS CUI [1,1])
C3543440 (UMLS CUI [1,2])
Clinical Trial Participation Status
Item
Subjects who are currently participating in a clinical trial in which the subject is or will be exposed to an investigational or noninvestigational drug or device, or have done so within the preceding 3 months.
boolean
C2348568 (UMLS CUI [1])
Protocol Compliance
Item
Subjects who, in the opinion of the investigator, would be noncompliant with the visit schedule or study procedures.
boolean
C0525058 (UMLS CUI [1])